Mark Dvorozniak

Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

Joseph Grimsby, Ramakanth Sarabu, Wendy L. Corbett et al. · Science · 2003 · 531 citations

Glucose Affinity, Glycosylation, Medicine +15

Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Martha J. Kelly, Sherrie Pietranico-Cole, J. Douglas Larigan et al. · Journal of Medicinal Chemistry · 2014 · 205 citations · Full text

Pharmacotherapy, Experimental Pharmacology, Central Thyroid Axis +16

Characterization of Glucokinase Regulatory Protein-deficient Mice

Joseph Grimsby, John W. Coffey, Mark Dvorozniak et al. · Journal of Biological Chemistry · 2000 · 136 citations · Full text

Null Mice, Pathology, Cellular Physiology +25

Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients

Ramakanth Sarabu, Fred T. Bizzarro, Wendy L. Corbett et al. · Journal of Medicinal Chemistry · 2012 · 97 citations · Full text

Glycobiology, Metabolomic Profiling, Pathology +21

Discovery, Structure−Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2<i>R</i>)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-<i>N</i>-thiazol-2-yl-propionamide (RO0281675)

Nancy-Ellen Haynes, Wendy L. Corbett, Fred T. Bizzarro et al. · Journal of Medicinal Chemistry · 2010 · 45 citations

Pharmaceutical Science, Glycobiology, Glucose Homeostasis +22